{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T02:09:57Z","timestamp":1772849397120,"version":"3.50.1"},"reference-count":45,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018694","name":"HORIZON EUROPE Marie Sklodowska-Curie Actions","doi-asserted-by":"publisher","award":["MSCA4Ukraine, 1233336 TBpreparadness4Ukraine"],"award-info":[{"award-number":["MSCA4Ukraine, 1233336 TBpreparadness4Ukraine"]}],"id":[{"id":"10.13039\/100018694","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010665","name":"H2020 Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","award":["823854 (INNOVA4TB)"],"award-info":[{"award-number":["823854 (INNOVA4TB)"]}],"id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000921","name":"European Cooperation in Science and Technology","doi-asserted-by":"publisher","award":["ADVANCE-TB (CA21164)"],"award-info":[{"award-number":["ADVANCE-TB (CA21164)"]}],"id":[{"id":"10.13039\/501100000921","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI19\/01408 and PI22\/01834"],"award-info":[{"award-number":["PI19\/01408 and PI22\/01834"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Respir Dis"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Ukraine remains a high World Health Organization priority country for drug-resistant tuberculosis (TB). Rifampicin-resistant TB (RR-TB) has a more protracted, more complicated, and more expensive treatment. In 2021, Ukraine reported 4025 RR-TB cases \u2013 5.4 times more (751) than all 30 European Union\/ European Economic Area countries together.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>The objective of the study was to determine the diagnostic accuracy of line probe assay (LPA), AID Autoimmun Diagnostika GmbH, for detecting resistance to anti-TB drugs and its clinical application for selecting treatment regimens.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>A prospective observational cohort study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>From May 2019 to June 2020, we consecutively enrolled patients with active TB hospitalized at the Regional Phthisiopulmonology Center (Vinnytsia, Ukraine), aged between 18 and 82\u2009years. The LPA was performed in the Genetic Research Laboratory at National Pirogov Memorial Medical University, Vinnytsia, Ukraine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of 84 clinical specimens and 97 culture isolates from 126 TB patients were tested during the study. Accuracy (95% confidence interval) of LPA for clinical samples in comparison with phenotypic drug susceptibility test (DST) was 80.1 (68.5\u201389.0) for isoniazid (H), 74.7 (62.4\u201384.6) for rifampicin (R), 74.4 (62.5\u201384.1) for ethambutol, 71.4 (41.9\u201391.6) for streptomycin, 84.6 (62.4\u201396.5) for prothionamide\/ethionamide, and 84.6 (73.6\u201392.3) for levofloxacin (Lfx), respectively. We found a significantly higher sensitivity of LPA for H, R, and Lfx for the culture isolates compared to clinical specimens ( p\u2009&lt;\u20090.05). LPA detected different mutations in 6 out of 17 (35.5%) patients susceptible to R by Xpert. A shorter treatment regimen with an injectable agent demonstrated a low suitability rate of 5% (8\/156) in a cohort of RR-TB patients from Ukraine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Initial LPA testing accurately identifies resistance to anti-TB drugs and facilitates the selection of an appropriate treatment regimen, minimizing exposure to empirical therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/17534666241249841","type":"journal-article","created":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T01:53:10Z","timestamp":1717120390000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Impact of line probe assay-based molecular testing on individualized treatment in patients with rifampicin-resistant tuberculosis: data from the prospective INNOVA4TB cohort study in Ukraine"],"prefix":"10.1177","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8780-9480","authenticated-orcid":false,"given":"Andrii","family":"Dudnyk","sequence":"first","affiliation":[{"name":"Department of Tuberculosis, Clinical Immunology and Allergy, National Pirogov Memorial Medical University, 56 Pyrogova St., Vinnytsia 21018, Ukraine"},{"name":"Institut d\u2019Investigaci\u00f3 Germans Trias i Pujol (IGTP), Mar Building, P1-18, Carretera de Can Ruti, Cam\u00ed de les Escoles s\/n, Badalona 08916, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Hempel","sequence":"additional","affiliation":[{"name":"AID\/GenID GmbH, Stra\u00dfberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oksana","family":"Lytvyniuk","sequence":"additional","affiliation":[{"name":"Department of Tuberculosis, Clinical Immunology and Allergy, National Pirogov Memorial Medical University, Vinnytsia, Ukraine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Halyna","family":"Liudkevych","sequence":"additional","affiliation":[{"name":"Genetic Research Laboratory, National Pirogov Memorial Medical University, Vinnytsia, Ukraine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Volodymyr","family":"Matsera","sequence":"additional","affiliation":[{"name":"Department of Drug-Resistant Tuberculosis, Regional Phthisiopulmonology Center, Bohonyky, Vinnytsia Region, Ukraine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetiana","family":"Nikitchenko","sequence":"additional","affiliation":[{"name":"Department of Drug-Resistant Tuberculosis, Regional Phthisiopulmonology Center, Bohonyky, Vinnytsia Region, Ukraine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Svitlana","family":"Blyzniuk","sequence":"additional","affiliation":[{"name":"Department of Drug-Susceptible Tuberculosis, Regional Phthisiopulmonology Center, Bohonyky, Vinnytsia Region, Ukraine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Molina-Moya","sequence":"additional","affiliation":[{"name":"Institut d\u2019Investigaci\u00f3 Germans Trias i Pujol (IGTP), Badalona, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosemarie","family":"Preyer","sequence":"additional","affiliation":[{"name":"AID\/GenID GmbH, Stra\u00dfberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Dom\u00ednguez","sequence":"additional","affiliation":[{"name":"Institut d\u2019Investigaci\u00f3 Germans Trias i Pujol (IGTP), Badalona, Barcelona, Spain"},{"name":"Department of Genetics and Microbiology, Universitat Aut\u00f2noma de Barcelona, Badalona, Barcelona, Spain"},{"name":"CIBER Enfermedades Respiratorias, Badalona, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2024,5,30]]},"reference":[{"key":"bibr1-17534666241249841","unstructured":"World Health Organization. Global tuberculosis report 2022, World Health Organization, Geneva, Licence: CC BY-NC-SA 3.0 IGO, https:\/\/www.who.int\/publications\/i\/item\/9789240061729 (2022, accessed 16 November 2023)."},{"key":"bibr2-17534666241249841","unstructured":"World Health Organization. Catalogue of mutations in\n                      Mycobacterium tuberculosis\n                      complex and their association with drug resistance, WHO | World Health Organization, https:\/\/www.who.int\/publications\/i\/item\/9789240028173 (2021, accessed 17 October 2023)."},{"key":"bibr3-17534666241249841","unstructured":"World Health Organization. Rapid communication: key changes to the treatment of drug-resistant tuberculosis, https:\/\/www.who.int\/publications\/i\/item\/WHO-UCN-TB-2022-2 (2022, accessed 16 September 2023)."},{"key":"bibr4-17534666241249841","unstructured":"UNHCR Operational Data Portal (ODP). Ukraine situation Flash update #36, UNHCR Regional Bureau for Europe, https:\/\/data.unhcr.org\/en\/documents\/details\/97261 (2022, accessed 1 September 2023)."},{"key":"bibr5-17534666241249841","unstructured":"ReliefWeb. Emergency appeal revised operational strategy. Europe | Ukraine and impacted countries crisis, Regional Office for Europe, Head of Disaster, Climate and Crisis Prevention Response and Recovery, https:\/\/reliefweb.int\/report\/ukraine\/europe-ukraine-and-impacted-countries-crisis-emergency-appeal-revised-operational-strategy (2023, accessed 19 October 2023)."},{"key":"bibr6-17534666241249841","unstructured":"World Health Organization. Meeting report of the who expert consultation on the definition of extensively drug-resistant tuberculosis. WHO, https:\/\/www.who.int\/publications\/i\/item\/meeting-report-of-the-who-expert-consultation-on-the-definition-of-extensively-drug-resistant-tuberculosis (2021, accessed 14 July 2023)."},{"key":"bibr7-17534666241249841","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa621"},{"key":"bibr8-17534666241249841","unstructured":"European Centre for Disease Prevention and Control, WHO Regional Office for Europe. Tuberculosis surveillance and monitoring in Europe 2023 \u2013 2021 data, European Centre for Disease Prevention and Control and Copenhagen: WHO Regional Office for Europe, Stockholm, https:\/\/www.ecdc.europa.eu\/sites\/default\/files\/documents\/tuberculosis-surveillance-monitoring-2023.pdf (2023, accessed 27 February 2024)."},{"key":"bibr9-17534666241249841","unstructured":"Public Health Center. Analytical surveillance data for Tuberculosis in Ukraine, 2022, Public Health Center, Kyiv, https:\/\/www.phc.org.ua\/sites\/default\/files\/users\/user90\/TB_surveillance_statistical-information_2022_dovidnyk.pdf (2023, accessed 28 February 2024)."},{"key":"bibr10-17534666241249841","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00875-1"},{"key":"bibr11-17534666241249841","unstructured":"World Health Organization. WHO consolidated guidelines on tuberculosis: module 3: diagnosis: rapid diagnostics for tuberculosis detection 2021 update, WHO, https:\/\/www.who.int\/publications\/i\/item\/9789240029415 (2021, accessed 12 September 2023)."},{"key":"bibr12-17534666241249841","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2014.09.010"},{"key":"bibr13-17534666241249841","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2019.06.001"},{"key":"bibr14-17534666241249841","doi-asserted-by":"publisher","DOI":"10.1016\/j.jctube.2020.100176"},{"key":"bibr15-17534666241249841","doi-asserted-by":"publisher","DOI":"10.1186\/s12866-020-01967-5"},{"key":"bibr16-17534666241249841","unstructured":"World Health Organization. WHO treatment guidelines for drug resistant tuberculosis 2016, update, October 2016 revision, https:\/\/www.who.int\/publications\/i\/item\/9789241549639 (2016, accessed 10 July 2023)."},{"key":"bibr17-17534666241249841","unstructured":"World Health Organization. WHO consolidated guidelines on tuberculosis: module 4: treatment \u2013 drug-resistant tuberculosis treatment, 2022 update, World Health Organization, Geneva, Licence: CC BY-NC-SA 3.0 IGO, https:\/\/www.who.int\/publications\/i\/item\/9789240063129 (2022, accessed 14 September 2023)."},{"key":"bibr18-17534666241249841","unstructured":"World Health Organization. Rapid communication: key changes to treatment of multidrug- and rifampicin-resistant tuberculosis (MDR\/RR-TB). WHO\/CDS\/TB\/2018.18, World Health Organization, https:\/\/apps.who.int\/iris\/handle\/10665\/275383 (2018, accessed 10 July 2023)."},{"key":"bibr19-17534666241249841","unstructured":"South African National Department of Health. Interim clinical guidance for the implementation of injectable-free regimens for rifampicin-resistant tuberculosis in adults, adolescents and children, NDoH, Pretoria, South Africa, https:\/\/www.tbonline.info\/media\/uploads\/documents\/dr_tb_clinical_guidelines_for_rsa_september_2018.pdf (2018, accessed 15 July 2023)."},{"key":"bibr20-17534666241249841","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-012799"},{"key":"bibr21-17534666241249841","unstructured":"World Health Organization. Technical manual for drug susceptibility testing of medicines used in the treatment of tuberculosis, World Health Organization, Geneva, Licence: CC BY-NC-SA 3.0 IGO, https:\/\/apps.who.int\/iris\/handle\/10665\/275469 (2018, accessed 20 July 2023)."},{"key":"bibr22-17534666241249841","unstructured":"World Health Organization. Line probe assays for detection of drug-resistant tuberculosis: interpretation and reporting manual for laboratory staff and clinicians, WHO, https:\/\/www.who.int\/publications\/i\/item\/9789240046665 (2022, accessed 14 July 2023)."},{"key":"bibr23-17534666241249841","unstructured":"Schoonjans F. MedCalc\u2019s diagnostic test evaluation calculator. MedCalc, https:\/\/www.medcalc.org\/calc\/diagnostic_test.php (accessed 30 January 2024)."},{"key":"bibr24-17534666241249841","unstructured":"Social Science Statistics. Z score calculator for 2 population proportions, https:\/\/www.socscistatistics.com\/tests\/ztest\/default2.aspx (accessed 30 January 2024)."},{"key":"bibr25-17534666241249841","unstructured":"Public Health Center. TB surveillance statistical information 2019, Ministry of Health of Ukraine, https:\/\/www.phc.org.ua\/sites\/default\/files\/users\/user90\/TB_surveillance_statistical-information_2019_dovidnyk.pdf (2022, accessed 17 July 2023)."},{"key":"bibr26-17534666241249841","unstructured":"World Health Organization. Target product profile for next-generation drug-susceptibility testing at peripheral centres, World Health Organization, Geneva, Licence: CC BY-NC-SA 3.0 IGO, https:\/\/www.who.int\/publications\/i\/item\/9789240032361 (2021, accessed 16 July 2023)."},{"key":"bibr27-17534666241249841","unstructured":"World Health Organization. WHO operational handbook on tuberculosis module 4: treatment \u2013 drug-susceptible tuberculosis treatment, World Health Organization, Geneva, https:\/\/www.who.int\/publications\/i\/item\/9789240050761 (2022, accessed 25 September 2023)."},{"key":"bibr28-17534666241249841","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2117166"},{"key":"bibr29-17534666241249841","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02169-16"},{"key":"bibr30-17534666241249841","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00398-14"},{"key":"bibr31-17534666241249841","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00166-2022"},{"key":"bibr32-17534666241249841","unstructured":"World Health Organization. Technical report on critical concentrations for drug susceptibility testing of medicines used in the treatment of drug-resistant tuberculosis, World Health Organization, Geneva (WHO\/CDS\/TB\/2018.5), Licence: CC BY-NC-SA 3.0 IGO, https:\/\/www.who.int\/publications\/i\/item\/WHO-CDS-TB-2018.5 (2018, accessed 23 August 2023)."},{"key":"bibr33-17534666241249841","doi-asserted-by":"publisher","DOI":"10.3201\/eid2603.190525"},{"key":"bibr34-17534666241249841","unstructured":"Stop TB Partnership. Molecular line probe assays for rapid screening of patients at risk of multi-drug resistant tuberculosis, Expert group report, Stop TB Partnership, https:\/\/stoptb.org\/assets\/documents\/about\/cb\/meetings\/15\/2.08-11%20Rolling%20out%20diagnostics%20in%20the%20field\/2.08-11.2%20Line%20Probe%20Assays.pdf (2008, accessed 14 July 2023)."},{"key":"bibr35-17534666241249841","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00452-7"},{"key":"bibr36-17534666241249841","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.21.0154"},{"key":"bibr37-17534666241249841","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01075-2016"},{"key":"bibr38-17534666241249841","unstructured":"Roscigno G. Drug resistant TB and new diagnostics for people living with HIV: emerging results from FIND, IAS Conference; Catalysing HIV\/TB research, http:\/\/www.stoptb.org\/wg\/tb_hiv\/assets\/documents\/DRUGRE~1.PDF (2009, accessed 15 July 2023)."},{"key":"bibr39-17534666241249841","doi-asserted-by":"publisher","DOI":"10.1016\/j.meegid.2021.105142"},{"key":"bibr40-17534666241249841","doi-asserted-by":"publisher","DOI":"10.1186\/s12941-021-00478-z"},{"key":"bibr41-17534666241249841","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01164-21"},{"key":"bibr42-17534666241249841","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201606-1097LE"},{"key":"bibr43-17534666241249841","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00537-2020"},{"key":"bibr44-17534666241249841","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201910-1960OC"},{"key":"bibr45-17534666241249841","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.21.0590"}],"container-title":["Therapeutic Advances in Respiratory Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17534666241249841","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17534666241249841","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17534666241249841","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T22:57:52Z","timestamp":1740869872000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17534666241249841"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":45,"alternative-id":["10.1177\/17534666241249841"],"URL":"https:\/\/doi.org\/10.1177\/17534666241249841","relation":{"has-review":[{"id-type":"doi","id":"10.1177\/17534666241249841\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666241249841\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666241249841\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666241249841\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666241249841\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666241249841\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666241249841\/v1\/review3","asserted-by":"object"}]},"ISSN":["1753-4666","1753-4666"],"issn-type":[{"value":"1753-4666","type":"print"},{"value":"1753-4666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]},"article-number":"17534666241249841"}}